Pfenex Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Pfenex Inc. – Product Pipeline Review – 2016’, provides an overview of the Pfenex Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Pfenex Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Pfenex Inc.

The report provides overview of Pfenex Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Pfenex Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Pfenex Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Pfenex Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pfenex Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pfenex Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Pfenex Inc. Snapshot 5

Pfenex Inc. Overview 5

Key Information 5

Key Facts 5

Pfenex Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Pfenex Inc. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pfenex Inc. - Pipeline Products Glance 12

Pfenex Inc. - Clinical Stage Pipeline Products 12

Phase I Products/Combination Treatment Modalities 12

Pfenex Inc. - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Pfenex Inc. - Drug Profiles 14

ranibizumab biosimilar 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

interferon beta-1b 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

Px-563L 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

teriparatide biosimilar 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

certolizumab pegol biosimilar 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

pegaspargase biosimilar 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

pegfilgrastim 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

peginterferon alfa-2a 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

PF-726 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Px-533 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Px-563L Second Generation 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

somatropin 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Pfenex Inc. - Pipeline Analysis 27

Pfenex Inc. - Pipeline Products by Target 27

Pfenex Inc. - Pipeline Products by Route of Administration 28

Pfenex Inc. - Pipeline Products by Molecule Type 29

Pfenex Inc. - Pipeline Products by Mechanism of Action 30

Pfenex Inc. - Recent Pipeline Updates 31

Pfenex Inc. - Dormant Projects 33

Pfenex Inc. - Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

List of Tables

Pfenex Inc., Key Information 5

Pfenex Inc., Key Facts 5

Pfenex Inc. – Pipeline by Indication, 2016 7

Pfenex Inc. – Pipeline by Stage of Development, 2016 8

Pfenex Inc. – Monotherapy Products in Pipeline, 2016 9

Pfenex Inc. – Partnered Products in Pipeline, 2016 10

Pfenex Inc. – Partnered Products/ Combination Treatment Modalities, 2016 11

Pfenex Inc. – Phase I, 2016 12

Pfenex Inc. – Preclinical, 2016 13

Pfenex Inc. – Pipeline by Target, 2016 27

Pfenex Inc. – Pipeline by Route of Administration, 2016 28

Pfenex Inc. – Pipeline by Molecule Type, 2016 29

Pfenex Inc. – Pipeline Products by Mechanism of Action, 2016 30

Pfenex Inc. – Recent Pipeline Updates, 2016 31

Pfenex Inc. – Dormant Developmental Projects,2016 33

Pfenex Inc., Subsidiaries 34

List of Figures

List of Figures

Pfenex Inc. – Pipeline by Top 10 Indication, 2016 7

Pfenex Inc. – Pipeline by Stage of Development, 2016 8

Pfenex Inc. – Monotherapy Products in Pipeline, 2016 9

Pfenex Inc. – Pipeline by Top 10 Target, 2016 27

Pfenex Inc. – Pipeline by Route of Administration, 2016 28

Pfenex Inc. – Pipeline by Molecule Type, 2016 29

Pfenex Inc. – Pipeline Products by Mechanism of Action, 2016 30

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports